Filter By Category
Archives
Share on -
DULIGOTUMAB
Generic Name: DULIGOTUMAB
ABSTRACT -
Duligotumab is an investigational dual-action monoclonal antibody targeting EGFR and HER3/ERBB3 signaling pathways in cancer.
DOSAGE -
No approved dosage. Intravenous dosing followed clinical trial protocols.
SIDE EEFECTS -
- Rash or acneiform dermatitis
- Diarrhea
- Fatigue
- Hypomagnesemia or electrolyte changes
- Infusion-related reactions
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Infusion hypersensitivity
- Urticaria
- Angioedema
- Anaphylaxis (rare)
DRUG INTERACTIONS-
- Other EGFR/HER inhibitors may increase dermatologic and gastrointestinal toxicity
- Immunosuppressants may blunt response
- Avoid live vaccines during anticancer biologic therapy
PREAUTONS–
- Monitor skin toxicity, diarrhea, electrolytes, and infusion reactions
- Use contraception per protocol
- Specialist oncology supervision required
WARNINGS –
- Investigational agent
- Severe infusion reactions and dermatologic toxicity are possible
Share on -
. Developed by